Results of the TEXT and SOFT studies in premenopausal women with hormone receptor-positive breast cancer were presented at the ASCO plenary session. The TEXT trial enrolled 2,672 women who were assigned to receive exemestane and ovarian function suppression (OFS) for 5 years or tamoxifen and OFS following surgery; in the SOFT trial, 3,066 women were randomly assigned to the same regimens or monotherapy with tamoxifen after surgery or within 8 months of neoadjuvant or adjuvant chemotherapy. After 5 years, disease-free survival (DFS) for exemestane and OFS was 91.1%, and 87.3% for tamoxifen and OFS, showing that combining OFS with exemestane is more effective than with tamoxifen.
References
Pagani, O. et al. Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone-receptor-positive (HR+) early breast cancer (BC): joint analysis of IBCSG TEXT and SOFT trials [abstract]. ASCO Annual Meeting 2014 LBA1 (2014)
Rights and permissions
About this article
Cite this article
Ovarian function suppression plus exemestane improves DFS. Nat Rev Clin Oncol 11, 380 (2014). https://doi.org/10.1038/nrclinonc.2014.108
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2014.108